YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages

Tsong Long Hwang, Ming Chi Tang, Liang Mou Kuo, Wen De Chang, Pei Jen Chung, Ya Wen Chang, Yao Ching Fang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Alveolar macrophages play significant roles in the pathogenesis of several inflammatory lung diseases. Increases in exhaled nitric oxide (NO) are well documented to reflect disease severity in the airway. In this study, we investigated the effect of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), a known activator of soluble guanylyl cyclase, on prostaglandin (PG)E 1 (a stable PGE 2 analogue) and forskolin (a adenylate cyclase activator) induced NO production and inducible NO synthase (iNOS) expression in rat alveolar macrophages (NR8383). YC-1 did not directly cause NO production or iNOS expression, but drastically potentiated PGE 1- or forskolin-induced NO production and iNOS expression in NR8383 alveolar macrophages. Combination treatment with YC-1 and PGE 1 significantly increased phosphorylation of the cAMP response element-binding protein (CREB), but not nuclear factor (NF)-κB activation. The combined effect on NO production, iNOS expression, and CREB phosphorylation was reversed by a protein kinase (PK)A inhibitor (H89), suggesting that the potentiating functions were mediated through a cAMP/PKA signaling pathway. Consistent with this, cAMP analogues, but not the cGMP analogue, caused NO release, iNOS expression, and CREB activation. YC-1 treatment induced an increase in PGE 1-induced cAMP formation, which occurred through the inhibition of cAMP-specific phosphodiesterase (PDE) activity. Furthermore, the combination of rolipram (an inhibitor of PDE4), but not milronone (an inhibitor of PDE3), and PGE 1 also triggered NO production and iNOS expression. In summary, YC-1 potentiates PGE 1-induced NO production and iNOS expression in alveolar macrophages through inhibition of cAMP PDE activity and activation of the cAMP/PKA/CREB signaling pathway.

Original languageEnglish
Pages (from-to)193-200
Number of pages8
JournalToxicology and Applied Pharmacology
Volume260
Issue number2
DOIs
Publication statusPublished - Apr 15 2012
Externally publishedYes

Fingerprint

Cyclic AMP Response Element-Binding Protein
Alveolar Macrophages
Prostaglandins E
Nitric Oxide
Chemical activation
Nitric Oxide Synthase
Phosphorylation
Phosphoric Diester Hydrolases
Colforsin
Phosphodiesterase 3 Inhibitors
Indazoles
Phosphodiesterase 4 Inhibitors
Rolipram
Pulmonary diseases
Guanylate Cyclase
Nitric Oxide Synthase Type II
Protein Kinase Inhibitors
Cyclic AMP-Dependent Protein Kinases
Adenylyl Cyclases
Lung Diseases

Keywords

  • Alveolar macrophage
  • cAMP
  • cGMP
  • Nitric oxide
  • Phosphodiesterase
  • YC-1

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages. / Hwang, Tsong Long; Tang, Ming Chi; Kuo, Liang Mou; Chang, Wen De; Chung, Pei Jen; Chang, Ya Wen; Fang, Yao Ching.

In: Toxicology and Applied Pharmacology, Vol. 260, No. 2, 15.04.2012, p. 193-200.

Research output: Contribution to journalArticle

Hwang, Tsong Long ; Tang, Ming Chi ; Kuo, Liang Mou ; Chang, Wen De ; Chung, Pei Jen ; Chang, Ya Wen ; Fang, Yao Ching. / YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages. In: Toxicology and Applied Pharmacology. 2012 ; Vol. 260, No. 2. pp. 193-200.
@article{8c3b5307055a44679bbcfd60ec2d669f,
title = "YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages",
abstract = "Alveolar macrophages play significant roles in the pathogenesis of several inflammatory lung diseases. Increases in exhaled nitric oxide (NO) are well documented to reflect disease severity in the airway. In this study, we investigated the effect of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), a known activator of soluble guanylyl cyclase, on prostaglandin (PG)E 1 (a stable PGE 2 analogue) and forskolin (a adenylate cyclase activator) induced NO production and inducible NO synthase (iNOS) expression in rat alveolar macrophages (NR8383). YC-1 did not directly cause NO production or iNOS expression, but drastically potentiated PGE 1- or forskolin-induced NO production and iNOS expression in NR8383 alveolar macrophages. Combination treatment with YC-1 and PGE 1 significantly increased phosphorylation of the cAMP response element-binding protein (CREB), but not nuclear factor (NF)-κB activation. The combined effect on NO production, iNOS expression, and CREB phosphorylation was reversed by a protein kinase (PK)A inhibitor (H89), suggesting that the potentiating functions were mediated through a cAMP/PKA signaling pathway. Consistent with this, cAMP analogues, but not the cGMP analogue, caused NO release, iNOS expression, and CREB activation. YC-1 treatment induced an increase in PGE 1-induced cAMP formation, which occurred through the inhibition of cAMP-specific phosphodiesterase (PDE) activity. Furthermore, the combination of rolipram (an inhibitor of PDE4), but not milronone (an inhibitor of PDE3), and PGE 1 also triggered NO production and iNOS expression. In summary, YC-1 potentiates PGE 1-induced NO production and iNOS expression in alveolar macrophages through inhibition of cAMP PDE activity and activation of the cAMP/PKA/CREB signaling pathway.",
keywords = "Alveolar macrophage, cAMP, cGMP, Nitric oxide, Phosphodiesterase, YC-1, Alveolar macrophage, cAMP, cGMP, Nitric oxide, Phosphodiesterase, YC-1",
author = "Hwang, {Tsong Long} and Tang, {Ming Chi} and Kuo, {Liang Mou} and Chang, {Wen De} and Chung, {Pei Jen} and Chang, {Ya Wen} and Fang, {Yao Ching}",
year = "2012",
month = "4",
day = "15",
doi = "10.1016/j.taap.2012.02.011",
language = "English",
volume = "260",
pages = "193--200",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages

AU - Hwang, Tsong Long

AU - Tang, Ming Chi

AU - Kuo, Liang Mou

AU - Chang, Wen De

AU - Chung, Pei Jen

AU - Chang, Ya Wen

AU - Fang, Yao Ching

PY - 2012/4/15

Y1 - 2012/4/15

N2 - Alveolar macrophages play significant roles in the pathogenesis of several inflammatory lung diseases. Increases in exhaled nitric oxide (NO) are well documented to reflect disease severity in the airway. In this study, we investigated the effect of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), a known activator of soluble guanylyl cyclase, on prostaglandin (PG)E 1 (a stable PGE 2 analogue) and forskolin (a adenylate cyclase activator) induced NO production and inducible NO synthase (iNOS) expression in rat alveolar macrophages (NR8383). YC-1 did not directly cause NO production or iNOS expression, but drastically potentiated PGE 1- or forskolin-induced NO production and iNOS expression in NR8383 alveolar macrophages. Combination treatment with YC-1 and PGE 1 significantly increased phosphorylation of the cAMP response element-binding protein (CREB), but not nuclear factor (NF)-κB activation. The combined effect on NO production, iNOS expression, and CREB phosphorylation was reversed by a protein kinase (PK)A inhibitor (H89), suggesting that the potentiating functions were mediated through a cAMP/PKA signaling pathway. Consistent with this, cAMP analogues, but not the cGMP analogue, caused NO release, iNOS expression, and CREB activation. YC-1 treatment induced an increase in PGE 1-induced cAMP formation, which occurred through the inhibition of cAMP-specific phosphodiesterase (PDE) activity. Furthermore, the combination of rolipram (an inhibitor of PDE4), but not milronone (an inhibitor of PDE3), and PGE 1 also triggered NO production and iNOS expression. In summary, YC-1 potentiates PGE 1-induced NO production and iNOS expression in alveolar macrophages through inhibition of cAMP PDE activity and activation of the cAMP/PKA/CREB signaling pathway.

AB - Alveolar macrophages play significant roles in the pathogenesis of several inflammatory lung diseases. Increases in exhaled nitric oxide (NO) are well documented to reflect disease severity in the airway. In this study, we investigated the effect of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), a known activator of soluble guanylyl cyclase, on prostaglandin (PG)E 1 (a stable PGE 2 analogue) and forskolin (a adenylate cyclase activator) induced NO production and inducible NO synthase (iNOS) expression in rat alveolar macrophages (NR8383). YC-1 did not directly cause NO production or iNOS expression, but drastically potentiated PGE 1- or forskolin-induced NO production and iNOS expression in NR8383 alveolar macrophages. Combination treatment with YC-1 and PGE 1 significantly increased phosphorylation of the cAMP response element-binding protein (CREB), but not nuclear factor (NF)-κB activation. The combined effect on NO production, iNOS expression, and CREB phosphorylation was reversed by a protein kinase (PK)A inhibitor (H89), suggesting that the potentiating functions were mediated through a cAMP/PKA signaling pathway. Consistent with this, cAMP analogues, but not the cGMP analogue, caused NO release, iNOS expression, and CREB activation. YC-1 treatment induced an increase in PGE 1-induced cAMP formation, which occurred through the inhibition of cAMP-specific phosphodiesterase (PDE) activity. Furthermore, the combination of rolipram (an inhibitor of PDE4), but not milronone (an inhibitor of PDE3), and PGE 1 also triggered NO production and iNOS expression. In summary, YC-1 potentiates PGE 1-induced NO production and iNOS expression in alveolar macrophages through inhibition of cAMP PDE activity and activation of the cAMP/PKA/CREB signaling pathway.

KW - Alveolar macrophage

KW - cAMP

KW - cGMP

KW - Nitric oxide

KW - Phosphodiesterase

KW - YC-1

KW - Alveolar macrophage

KW - cAMP

KW - cGMP

KW - Nitric oxide

KW - Phosphodiesterase

KW - YC-1

UR - http://www.scopus.com/inward/record.url?scp=84862814591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862814591&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2012.02.011

DO - 10.1016/j.taap.2012.02.011

M3 - Article

C2 - 22381622

AN - SCOPUS:84862814591

VL - 260

SP - 193

EP - 200

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 2

ER -